ScoreHaematology
IPS-E: prognosis of asymptomatic early-stage CLL
Estimates the risk of needing treatment in early, asymptomatic chronic lymphocytic leukaemia.
Updated 31 October 2026
When to use it
Patients with Binet A or Rai 0–II CLL without treatment indication, to plan follow-up.
What it needs
- Unmutated IGHV
- Lymphocytes > 15 × 10⁹/L
- Palpable lymph nodes
The points for each answer and the automatic total are in the app.
How to interpret it
| Result | Interpretation |
|---|---|
| ≤ 0 | Low risk: treatment at 5 years ≈ 8% |
| 1 | Intermediate risk: treatment at 5 years ≈ 28% |
| ≥ 2 | High risk: treatment at 5 years ≈ 61% |
Practical tip
It predicts time to first treatment, not survival: use CLL-IPI for that.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
